• By Sam Smith

Beating Advanced Cancers: New Epigenomic Block for Advanced Cancer Progression

June 16, 2015

SCOTTSDALE, Ariz. — An international research team led by Mayo Clinic oncologists has found a new way to identify and possibly stop the progression of many late-stage cancers, including bladder, blood, bonebrainlung and kidney.

The precision medicine study appears online in Oncogene and focuses on kidney cancer and its metastases. Recent studies of the same epigenomic fingerprint in other cancers suggest a common pathway that could help improve the diagnosis and treatment of advanced disease across a wide variety of cancer types.

“If you think of late-stage cancer as a runaway car, most of our drugs take a shot at a tire here and there, but sometimes they miss and often they can’t stop it entirely,” says Thai Ho, M.D., Ph.D., a Mayo Clinic oncologist and lead author of the study. “We believe we have identified a mechanism that seizes the cancer’s biological engine and could potentially stop it in its tracks.”

The new approach zeroes in on an epigenomic fingerprint in metastatic disease, in which the body often misinterprets a healthy genetic blueprint, producing toxic cells that run afoul of the body’s normal functions.

MEDIA CONTACT: Sam Smith, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu.

Dr. Ho and his colleagues are currently validating a test based on the newly identified epigenomic fingerprint, called H3K36me3 loss, which could help providers identify more aggressive cancers or find the best drug for the individual patient to further personalize medical care.

“This paper is the first report we know of translating this fingerprint into patient tissues, and efforts are ongoing to expand this to tumors beyond kidney cancer,” says Dr. Ho.

The test and a potential treatment are based on an emerging discipline of medical research called epigenomics, the complex biological process through which individual cells read their genetic blueprints and then determine what type of tissue to become.

Dr. Ho offers the example of honeybees as among the starkest examples of how epigenomics affects cellular function and an organism’s fate.

Throughout their life spans, all bees in a hive share the same DNA sequence. But some bees become drones, others sterile female workers, and still others the queen. Much of this differentiation can be attributed to epigenomics, says Dr. Ho.

In feeding a larval honeybee with copious amounts of a richly nutritious secretion called royal jelly, the larva will eventually develop into a queen. Chemicals present in the royal jelly, but absent in nectar and pollen, are thought to activate entirely different parts of the same bee genome — converting one larva into the queen while others, such as workers and drones, are much smaller and have shorter life spans. Similarly, cancers often subvert a cell’s normal epigenomic mechanisms to become more aggressive.

The study represents a collaborative effort from the Mayo Clinic Center for Individualized Medicine, spanning at all three Mayo sites: Mayo Clinic in Arizona, Mayo Clinic in Florida, and Mayo Clinic in Minnesota. Scientists and physicians at MD Anderson Cancer Center, Texas A&M University, Baylor College of Medicine, Van Andel Research Institute and National Cancer Centre Singapore contributed to this two-year study.

Funding comes from the National Institutes of Health, Mayo Clinic Center for Individualized Medicine and generous benefactors of Mayo Clinic.

Co-authors of the study are: In Young Park, Ph.D., and Cheryl Walker, Ph.D., both of Texas A&M University; Hao Zhao, Ph.D., Pan Tong, Ph.D., Anh Hoang, Pheroze Tamboli, M.D., Wei Qiao, Nizar Tannir, M.D., Jing Wang, Ph.D., Mien-Chie Hung, Ph.D., and Eric Jonasch, M.D., of MD Anderson Cancer Center; Karl Dykema, of Van Andel Research Institute; Bin Tean Teh, M.D., Ph.D., of Van Andel Research Institute and National Cancer Centre Singapore; Federico Monzon, M.D., of Baylor College of Medicine; and Mia Champion, Ph.D., Huihuang Yan, Ph.D., Alexander Parker, Ph.D., Richard Joseph, M.D., Erik Castle, M.D., and Rafael Nunez Nateras, M.D., of Mayo Clinic.


About the Mayo Clinic Center for Individualized Medicine
The Mayo Clinic Center for Individualized Medicine is home to the Individualized Medicine Clinic, the world’s first integrated, multidisciplinary genomics clinic, serving patients with advanced cancer and diagnostic dilemmas. The center discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient. Visit http://mayoresearch.mayo.edu/center-for-individualized-medicine/ for more information.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic and https://newsnetwork.mayoclinic.org/.



Nancy E

Posts: 1
Joined: Nov 12, 2013
Posted by @nancy8, Jun 17, 2015

My husband was just diagnosed today, from a biopsy done on Monday at Mayo Clinic, Rochester MN, with metatstic renal cell carcinoma to the lung. I am very interested in this study and the possiblity of this helping my husband. His intial renal cell carcinoma was 10 years ago. Thank you for your research and your help

Sam Smith

Posts: 30
Joined: Jun 27, 2013
Posted by @scolbysmith, Jun 18, 2015

I am so sorry to hear about your husband. I will reach out to Dr. Ho’s research coordinator and team. You should also feel free to do so. Even discuss the study and press release with your treating oncologist; he or she may know whether application of this technology is appropriate for your husband’s care. Please let me know how I can help further.

Samuel Smith | Public Affairs Specialist | Mayo Clinic | External Relations – Research Communications | 507-266-0607 office | 815-535-1902 cell | smith.samuel@mayo.edu


Posts: 1
Joined: Sep 21, 2015
Posted by @bmaguire, Sep 21, 2015

Hi there,
Are there clinical trials available to participate in worldwide?

Please login or register to post a comment.